Cancertain Test
Personalized Cancer Treatment Selection
Key Facts
About Cancertain
Cancertain is a private, early-stage diagnostics company operating in the functional precision oncology space. Its proprietary platform utilizes 3D cell culture of patient-derived tumor samples to empirically test drug sensitivity, providing oncologists with a personalized treatment plan to increase first-line therapy efficacy. The company appears to be in a commercial or early-revenue stage for its diagnostic service, having evolved from its earlier identity as 'CLYZ Labs' which secured seed funding and initiated clinical trials in 2018. Its primary market opportunity lies in addressing the high failure rate of standard chemotherapy regimens by offering a rapid, lab-based alternative to genomic profiling.
View full company profile